Drug Database
PI

pitavastatin + valsartan (Livalsartan / Livasartan)

✓ Approved

JW Pharmaceutical · AGTR1 · Small Molecule

What is pitavastatin + valsartan?

pitavastatin + valsartan is a small molecule developed by JW Pharmaceutical. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLivalsartan, Livasartan
CompanyJW Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetAGTR1, HMGCR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, JW Pharmaceutical

Mechanism of Action

Molecular Targets

pitavastatin + valsartan acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pitavastatin + valsartan is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedBMC cardiovascular disorders2026-05-24

Drug-induced psoriasis following sacubitril/valsartan: a case report and literature review.

Tang Tang T, Guo Mu M, Yu Huimin H, Zhang Yun Y et al.

Drug exposure is one of the potential mechanisms implicated in the onset or exacerbation of psoriasis. To date, several cardiovascular agents have been implicated. Sacubitril/valsartan (SV) has been widely used in the treatment of hypertension and heart failure (HF). Its common adverse reactions include angioedema, hypotension, renal impairment, and hyperkalemia. However, SV may cause psoriasis, which needs clinical attention. This report describes a case of a middle-aged male patient who developed psoriasis following SV therapy. The rashes presented as well-demarcated red or violaceous plaques with noticeable scaling. After being diagnosed with psoriasis, he was started on topical clobetasol propionate ointment, and SV was discontinued and replaced with ramipril for blood pressure control. During follow-up, the skin lesions showed marked improvement. However, the patient developed similar cutaneous manifestations again when SV was re-administered. He had previously developed psoriasis while using nifedipine, but transitioned to olmesartan and subsequently improved significantly with topical medication. Sacubitril enhances the effect of natriuretic peptides, which may be accompanied by a compensatory increase in angiotensin Ⅱ (Ang Ⅱ) levels, possibly contributing to the psoriasis. To the best of our knowledge, this is the first reported case worldwide of psoriasis potentially associated with SV, and the underlying mechanism appears likely to be related to sacubitril. It serves as a caution for clinicians prescribing SV, particularly in patients with a history of psoriasis or positivity for the HLA-Cw*0602 allele. Further studies are warranted to confirm the mechanism by which sacubitril induces psoriasis.

PMID 42177422
Read full article →
PubMedEuropean journal of heart failure2026-05-23

Cardiovascular events after acute myocardial infarction complicated by low ejection fraction and/or congestion: a landmark analysis of the PARADISE-MI trial.

Boulet Jacinthe J, Rouleau Jean-Lucien JL, Petrie Mark M, Claggett Brian B et al.

Despite improvements in post-acute myocardial infarction (AMI) care, the risk of subsequent cardiovascular (CV) events remains substantial, particularly heart failure (HF) in patients with left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. The PARADISE-MI trial randomized 5661 patients with AMI complicated by LVSD and/or pulmonary congestion to sacubitril/valsartan (97/103 mg bid) or ramipril (5 mg bid) at a mean of 4 days post-AMI. This post hoc analysis described the timing and distribution of CV events, and compared treatment effects in early (≤ 3 months) and late (> 3 months) post-AMI periods. Post-AMI, CV events peaked early; HF was the most frequent (16.2/100 patient-years (py)), followed by CV death (11.6/100 py) and recurrent MI (10.9/100 py). Later, HF remained predominant (3.2/100 py vs. 2.6/100 py for MI, p=0.008; CV death 2.1/100 py). Early post-AMI, patients with HF or recurrent MI shared similar profiles. Later, HF patients were predominantly older and female, with greater pulmonary congestion and lower eGFR; recurrent MI patients had more frequent history of coronary revascularization. Only sacubitril/valsartan showed a favorable influence late post-AMI (HR 0.76, 95% CI 0.60-1.00, p=0.05) and expanded CV composite outcome (CV death, HF events, recurrent MI, hospitalization for angina, or post-randomization coronary revascularization) benefit over the trial (HR=0.87, 95% CI 0.77-0.97, p=0.012). Post-AMI, HF predominates both early and late among CV events. Compared with ramipril, sacubitril/valsartan was associated with a possible late reduction in recurrent MI and a modest decrease in an expanded CV composite outcome that merits further investigation.

PMID 42175583
Read full article →
PubMedAmerican journal of translational research2026-05-22

Effects of sacubitril/valsartan combined with ivabradine in treating cardiorenal syndrome.

Li Guilan G, Liu Hongxia H, Zhou Siying S, Xiong Wen W

To investigate the effects of sacubitril/valsartan combined with ivabradine in treating cardiorenal syndrome (CRS). Information from 120 selected participants was retrospectively analyzed and divided into an experimental group (n=60) and a control group (n=60). The control group received sacubitril/valsartan alone, while the experimental group received sacubitril/valsartan plus ivabradine. Clinical efficacy, blood lipids, cardiac and renal function, and oxidative stress were observed in both groups. The experimental group showed better clinical efficacy, lipid metabolism, cardiac function, renal function, and oxidative stress than the control group, and a lower incidence of major adverse cardiovascular events (MACE) (all P<0.05). Sacubitril/valsartan combined with ivabradine is effective in treating CRS patients, with superior efficacy across various indicators and its usage has a lower incidence of MACE.

PMID 42170471
Read full article →
PubMedDrugs2026-05-21

Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial.

Lv Qiang Q, Ma Changsheng C, Wang Fang F, Li Lipeng L et al.

To evaluate the efficacy and safety of sitokiren (SPH3127) tablet in patients with mild-to-moderate essential hypertension in comparison to valsartan capsule. This multicentre, randomised, double-blind, parallel Phase III trial was designed in 2 stages. In the 1st stage, eligible patients were randomised to receive 50 mg, 100 mg or 200 mg of SPH3127 tablet or 80 mg of valsartan capsule once daily (QD) for 12 consecutive weeks. In the 2nd stage, eligible patients were randomised to receive assigned dose of SPH3127 tablet based on the results from the 1st stage or valsartan 80 mg QD for 12 consecutive weeks. Primary outcome was the change from baseline in mean sitting diastolic blood pressure (msDBP) at Week 12. Safety outcome measures included any adverse events. Exploratory outcomes included plasma concentration of SPH3127, as well as the assessment of the correlation between SPH3127 exposure with the level of renin inhibition, clinical efficacy and occurrence of adverse events. The 1st stage enrolled 189 patients, of which 129 eligible patients were randomised. High plasma renin activity (PRA) inhibitory effect (83%) and the biggest reduction of msDBP at Week 12 from baseline (- 8.17 ± 5.90 mmHg) was detected in SPH3127 group at the dosage of 100 mg, which was determined for the subsequent stage 2 of this trial. The 2nd stage screened 1260 patients, of which 828 eligible patients were randomised to receive SPH3127 tablet 100 mg (N = 413) and valsartan capsule 80 mg (N = 415), QD. Main analysis based on the treatment policy strategy indicated 5.97 (0.41) mmHg [least-square mean (LSM) and standard error (SE)] of the msDBP changes at Week 12 from baseline in the SPH3127 and 6.32 (0.41) in valsartan groups, with inter-group difference of - 0.35 mmHg (95% CI: - 1.48, 0.78, p = 0.005). Main analysis based on hypothetical strategy showed 5.95 (0.41) mmHg of the msDBP changes at Week 12 from baseline in the SPH3127 and 6.31 (0.42) mmHg in valsartan groups, with inter-group difference of - 0.36 mmHg (95% CI: - 1.51, 0.78, p = 0.006). During the 12-week treatment period, 250 (61.1%) patients in SPH3127 group and 231 (56.2%) patients in valsartan group reported treatment emergent adverse events (TEAEs). Adverse drug reaction (ADR) was reported by 34 (8.3%) and 41 (10.0%) patients in SPH3127 and valsartan group, respectively. The serious adverse events (SAEs) reported by 10 patients were considered not related to the investigational drugs. Death was reported in 1 patient in the valsartan group due to myocardial infarction, which was considered not related to the study drug. Oral SPH3127 tablet 100 mg QD is effective and safe for adult patients with mild-to-moderate essential hypertension. Clinicaltrials.gov Identifier number NCT05359068.

PMID 42165988
Read full article →
PubMedScientifica2026-05-21

Targeting NLRP3 Inflammasomes in Myocarditis: Potential Therapeutic Strategies and Clinical Translation.

Retnowati Faizah D FD, Halawa Dunia R DR, Maayah Zaid H ZH, Abdallah Atiyeh M AM

Myocarditis can be caused by viral infections, systematic autoimmune diseases, and as a reaction to prescribed medications, and the nucleotide-binding domain leucine-rich repeat pyrin domain-containing 3 (NLRP3) inflammasome is implicated in its pathophysiology. Here, we explore pharmaceutical and other therapies that modulate NLRP3 activation and may therefore be useful for treating myocarditis. Pharmaceutical agents such as colchicine, SGLT2 inhibitors (empagliflozin and canagliflozin), calpain inhibitors, and sacubitril/valsartan have shown promise in reducing inflammation and preserving cardiac function. Natural compounds, including morroniside and crocin, exhibit anti-inflammatory and cardioprotective effects by targeting the NLRP3 inflammasome. While these treatments have shown preclinical potential, successful clinical translation of inflammasome-targeting drugs will require efforts to overcome recruitment challenges, flawed trial designs, high dropout rates, safety and toxicity concerns, and a lack of biomarkers. Natural products may offer a practical solution to these issues, providing safer therapeutic options and providing innovative approaches for managing myocarditis and preventing long-term complications. Trial Registration: ClinicalTrials.gov identifier: NCT05855746.

PMID 42163845
Read full article →
PubMedBMC cardiovascular disorders2026-05-20

Effects of Qili Qiangxin granules in combination with Entresto on quantitative parameters of myocardial motion in patients with cardiomyopathy in end-stage renal disease.

Li Yanxia Y, Liu Lin L, Wang Fengrong F

Cardiomyopathy is a devastating complication of end-stage renal disease (ESRD), characterized by complex remodeling and high cardiovascular mortality. While sacubitril/valsartan (Sac/Val) and Qili Qiangxin (QLQX) granules have shown individual benefits in heart failure, their combined efficacy in ESRD patients remains poorly defined. To evaluate the impact of adjunctive QLQX therapy with Sac/Val on quantitative myocardial motion, cardiac function, and hemodynamic parameters in patients with ESRD. In this retrospective cohort study, 109 ESRD patients with heart failure with reduced ejection fraction (HFrEF) were enrolled. Patients were divided into a control group (n = 53, Sac/Val alone) and an observation group (n = 56, Sac/Val plus QLQX). Comprehensive 2D and 4D echocardiography, including speckle-tracking for global longitudinal strain (GLS), was performed after 3 months of treatment. Compared to the control group, the observation group demonstrated significantly higher left ventricular ejection fraction ( LVEF, 45.2 ± 5.8% vs. 40.5 ± 5.2%, t = 4.446, P<0.0001) and improved GLS (-17.1 ± 2.3% vs. -15.2 ± 2.1%, P = 0.018). Significant enhancements were also observed in peak systolic myocardial velocity, cardiac output, and left atrial emptying fraction (all P < 0.05). Furthermore, the observation group showed favorable shifts in diastolic indices (E/E' ratio and isovolumic relaxation time) and right ventricular performance (TAPSE and Tei index) (P < 0.05). The combination of QLQX and Sac/Val is associated with modest but statistically significant improvements in biventricular systolic and diastolic function in ESRD patients. These findings suggest a potential synergistic effect on myocardial mechanics, providing a hypothesis-generating basis for larger prospective trials.

PMID 42157107
Read full article →

+7254 more articles available with a free account

Sign up free to view all articles →

Ask about pitavastatin + valsartan